• Aliases: GA101, R05072759, R7159
    • A glycoengineered type II anti-CD20 monoclonal antibody that is expressed on the surface of pre B- and mature B-lymphocytes; upon binding to CD20, obinutuzumab activates complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and antibody-dependent cellular phagocytosis, resulting in cell death
    • FDA approved for CLL and follicular lymphoma
    • Recommended dose: (1) For CLL—cycle 1: 100 mg IV on day 1, followed by 900 mg on day 2, followed by 1,000 mg weekly for 2 doses. For cycles 2 to 6: 1,000 mg IV on day 1 of each 28-day cycle. th bendamustine) 1,000 mg IV weekly for 3 doses. For cycles 2 to 6: 1,000 mg IV on day 1 of each 28-day cycle. If used as monotherapy, 1,000 mg IV every 2 months for 2 years
    Other topics in Targeted and Immunotherapy Agents